ArticleMaterials today. Bio2026
Orchestrating the immuno-chondrogenic microenvironment via a bio-inorganic hybrid microsphere system for tendon-to-bone healing.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunoengineering in the field of tendon and bone regeneration: immunomodulatory biomaterials, delivery platforms, and preclinical models for chronic diseases.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The structural failure of rotator cuff repair is largely attributed to fibrovascular scar formation driven by a persistent inflammatory microenvironment and insufficient fibrocartilage regeneration at the tendon-to-bone interface. To address this, a microfluidic-generated GelMA microsphere system co-encapsulating Zeolitic Imidazolate Framework-8 (ZIF-8) nanoparticles and bone marrow mesenchymal stem cell (BMSC)-derived small extracellular vesicles (sEVs) is developed. This composite system (ZIF-8/sEVs@MS) enables the sustained release of Zn
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.